Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chipotle Mexican Grill, Inc. (CMG) vs Novo Nordisk A/S (NVO) Price & Performance

Chipotle Mexican Grill, Inc.Trade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Chipotle Mexican Grill, Inc. vs Novo Nordisk A/S — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.73 (market cap $40.49B), while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.1× Chipotle Mexican Grill, Inc.'s market cap, and Novo Nordisk A/S pays a 3.81% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.

CMGNVO
Market Cap
$40.49B$207.85B
Sector
Consumer CyclicalHealth
52-Week High
$44.04$63.98
52-Week Low
$28.17$35.29
Enterprise Value
$45.24B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chipotle Mexican Grill, Inc.

CMG trades at $32.71, up 1.76% on the day, with a bearish technical signal driven by moving averages. The company reported strong revenue growth to $11.93B in 2025 and has consistently beaten EPS estimates in recent quarters. However, net cash flow turned negative at -$392M due to aggressive financing activities. Recent news highlights a salmonella outbreak linked to jalapeños, creating near-term headwinds.

Wall Street maintains a bullish stance with a $42.17 consensus price target, representing 29% upside, and no sell ratings. Key risks include food safety issues, margin compression, and negative cash flow. The stock's high P/E of 29.63 requires sustained earnings growth to justify valuation.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Chipotle Mexican Grill, Inc.

Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.

Read more on CMG

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO